Mylab and Ekincare to promote Serum Institute’s nasal flu vaccine among corporates
- November 28, 2023
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
Mylab and Ekincare to promote Serum Institute’s nasal flu vaccine among corporates
Subject :Science and Tech
Section: Health
In the news:
- Diagnostics solutions provider Mylab is partnering with Ekincare to promote the nasal influenza vaccine NASOVAC-S4, developed by the Serum Institute of India (SII), among corporates.
Ekincare:
- Ekincare is a corporate health benefits platform and its collaboration with Mylab will enable businesses to incorporate NASOVAC-S4 into their employee wellness programs.
- Ekincare has a network of over 10,000 cashless healthcare service providers, making it one of India’s leading integrated OPD (out-patient department) benefits platforms
About NASOVAC-S4:
- It offers a non-invasive and painless alternative to traditional injections.
- It is administered through the nasal route.
- It includes two influenza Type A virus strains (A/H1N1 and A/H3N2) and two influenza Type B virus strains (Victoria and Yamagata lineage).
- It aims to reduce the impact of influenza on the workplace.
- Influenza is an acute respiratory infection caused by influenza viruses.
Source: TH BusinessLine